CGP 39551CGP 39551
MedChemExpress (MCE)
HY-107703
127910-32-1
Please store the product under the recommended conditions in the Certificate of Analysis.
Room temperature in continental US
may vary elsewhere.
CGP 39551 is a potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonist with potent anticonvulsant activity. CGP 39551 shows measurable inhibitory activity at both L-[3H]-glutamate (Ki=8.4 μM).
CGP 39551 inhibits the binding of the selective NMDA receptor antagonist, [3H]-CPP to rat brain postsynaptic densities (PSDs) with a Ki of 310 nM[2].
CGP 39551 exhibits maximal electroshock-induced seizures in mice with the ED50 of 4 mg/kg (p.o.)[2]. Following chronic neonatal treatment with CGP 39551, adult rats show increased behavioral responses to the D2 dopamine receptor stimulation[3].
| | | |
| | | | | |
[1]. G E Fagg,et al. CGP 37849 and CGP 39551: novel competitive N-methyl-D-aspartate receptor antagonists with potent oral anticonvulsant activity. Prog Clin Biol Res. 1990
361:421-7. [Content Brief]
[2]. G E Fagg, et al. CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. Br J Pharmacol. 1990 Apr
99(4):791-7. [Content Brief]
[3]. R Dall'Olio, et al. Chronic neonatal blockade of N-methyl-D-aspartate receptor by CGP 39551 increases dopaminergic function in adult rat. Neuroscience. 1994 Nov
63(2):451-5. [Content Brief]